This invention relates to medicine, in particular to pharmacology and psychiatry, and can be used for the manufacture of medications for treatment of treatment-resistant forms of schizophrenia. For this purpose we proposed the use of compounds 11-(piperazine-1-yl)-7-fluoro-8-chloro-5H-dibenzo[b,e][1,4]diazepine, 11-(4-methyl piperazine-1-yl)-7-fluoro-8-chloro-5H-dibenzo[b,e][1,4]diazepine, pharmaceutically acceptable salts, hydrates or solvates thereof. The invention allows developing an effective medication, the use of which in treatment of treatment-resistant forms of schizophrenia allows for eliminating both the positive and negative symptoms of schizophrenia, and cognitive disorders, and the use of which does not cause severe side effects that limit its use, including sedation, tachycardia, orthostatism, agranulocytosis and sialorrhea.
